DEFA14A: Prothena Reports Q3 2025 Results, Advances Clinical Pipeline

Prothena Corporation plc announced third quarter 2025 financial results and significant advancements in its late-stage clinical programs for neurodegenerative and rare diseases.

Summary

• Net cash used in operating and investing activities was $40.6 million for the third quarter of 2025 and $140.4 million for the first nine months of 2025.
• The company's cash, cash equivalents, and restricted cash position was $331.7 million as of September 30, 2025.
• Roche plans to initiate the Phase 3 PARAISO clinical trial evaluating prasinezumab for early-stage Parkinson's disease by the end of 2025.
• Novo Nordisk initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug for ATTR amyloidosis with cardiomyopathy.
• Novo Nordisk is scheduled to present Phase 2 results for coramitug during a late-breaking session at the American Heart Association Scientific Sessions on November 10, 2025.
• Bristol Myers Squibb obtained Fast Track designation from the U.S. FDA for BMS-986446 (PRX005), an anti-MTBR-tau-targeting antibody, for the treatment of Alzheimer's disease.
• Prothena has the potential to earn up to $105 million in aggregate clinical milestone payments by the end of 2026 related to the advancement of coramitug and PRX019.
• An Extraordinary General Meeting will be convened on November 19, 2025, to seek shareholder approval for a proposal to reduce share capital to create distributable reserves, supporting a potential share redemption program in 2026.
• Net loss was $36.5 million for the third quarter of 2025 and $222.5 million for the first nine months of 2025.
• Total revenue was $2.4 million for the third quarter of 2025 and $9.7 million for the first nine months of 2025, primarily from collaboration with Bristol Myers Squibb.
• Research and development (R&D) expenses decreased to $28.9 million for Q3 2025 and $120.3 million for the first nine months of 2025, compared to prior year periods.
• General and administrative (G&A) expenses decreased to $13.2 million for Q3 2025 and $46.7 million for the first nine months of 2025, compared to prior year periods.
• The first nine months of 2025 net loss includes $33.1 million in restructuring charges and a $43.2 million net non-cash income tax expense.
• The company continues to expect full year 2025 net cash used in operating and investing activities to be $170 million to $178 million, with an estimated year-end cash position of approximately $298 million (midpoint).

Sentiment

Score: 7

Explanation: The filing presents a mixed financial picture with significant losses but strong positive momentum in clinical pipeline advancement and strategic partnerships. The reaffirmation of financial guidance and plans for potential capital return to shareholders are positive, while the substantial net loss and reduced revenue compared to the prior year are negatives. The overall sentiment leans positive due to the progress in late-stage clinical assets and potential future milestones.

Positives

• Multiple late-stage partnered clinical programs are advancing, including prasinezumab, coramitug, and BMS-986446.
• Roche is set to initiate the Phase 3 PARAISO clinical trial for prasinezumab (Parkinson's disease) by the end of 2025.
• Novo Nordisk has initiated the Phase 3 CLEOPATTRA clinical trial for coramitug (ATTR amyloidosis with cardiomyopathy).
• BMS-986446 received Fast Track designation from the U.S. FDA for the treatment of Alzheimer's disease, potentially accelerating its development and review.
• The company has the potential to earn up to $105 million in aggregate clinical milestone payments by the end of 2026.
• R&D expenses decreased to $28.9 million for Q3 2025 and $120.3 million for the first nine months of 2025, primarily due to lower clinical trial, personnel, manufacturing, and consulting expenses.
• G&A expenses decreased to $13.2 million for Q3 2025 and $46.7 million for the first nine months of 2025, primarily due to lower personnel expenses.
• Prasinezumab is projected by Roche to have peak sales potential greater than $3.5 billion (unadjusted) and could be the first disease-modifying treatment for Parkinson's disease.

Negatives

• Reported a net loss of $36.5 million for the third quarter of 2025 and a significantly increased net loss of $222.5 million for the first nine months of 2025.
• The net loss for the first nine months of 2025 includes $33.1 million in restructuring charges and a $43.2 million net non-cash income tax expense.
• Total revenue for the first nine months of 2025 ($9.7 million) was substantially lower compared to $133.0 million for the same period in 2024.
• Net cash used in operating and investing activities was $40.6 million for Q3 2025 and $140.4 million for the first nine months of 2025, indicating continued cash burn.

Risks

• Uncertainties related to the completion of operational and financial closing procedures, audit adjustments, and other developments that may require adjustments to the preliminary financial results.
• Forward-looking statements are based on estimates, projections, and assumptions that may prove not to be accurate, and actual results could differ materially from those anticipated.
• Potential risks, uncertainties, and other important factors are detailed in the Risk Factors sections of the Quarterly Report on Form 10-Q to be filed with the SEC on November 6, 2025, and subsequent SEC filings.

Future Outlook

The company maintains its full year 2025 guidance, expecting net cash used in operating and investing activities to be between $170 million and $178 million, and an estimated year-end cash, cash equivalents, and restricted cash balance of approximately $298 million (midpoint). This guidance includes an estimated net loss of $240 million to $248 million, incorporating $36 million in non-cash share-based compensation and a $44.9 million non-cash income tax expense. The company also anticipates several clinical milestones by the end of 2026, including potential milestone payments of up to $105 million, and a potential share redemption program in 2026 subject to shareholder and board approval.

Management Comments

• "We are pleased with the advancement of our late-stage partnered clinical programs."
• "Novo Nordisk recently initiated the Phase 3 CLEOPATTRA clinical trial evaluating coramitug in ATTR-CM and Roche plans to initiate the Phase 3 PARAISO clinical trial evaluating prasinezumab in early-stage Parkinson's disease by the end of 2025."
• "Recently, Bristol Myers Squibb obtained Fast Track designation from the U.S. FDA for BMS-986446, an anti-MTBR-tau antibody, for the treatment of Alzheimer's disease."
• "We look forward to Novo Nordisk presenting Phase 2 coramitug results in a late-breaking presentation at the American Heart Association Scientific Sessions 2025."
• "Our Prothena scientists will be presenting a poster on our TDP-43 CYTOPE, a therapeutic modality enabling cytosolic delivery of macromolecules, which demonstrated a reduction in intracellular TDP-43 pathology in a preclinical ALS mouse model."

Industry Context

Prothena operates in the highly competitive and research-intensive biotechnology sector, focusing on protein dysregulation in neurodegenerative and rare peripheral amyloid diseases. The advancement of its partnered programs with major pharmaceutical companies like Roche, Novo Nordisk, and Bristol Myers Squibb highlights the industry's collaborative model for de-risking and accelerating drug development, particularly for complex conditions like Parkinson's, Alzheimer's, and ATTR amyloidosis. The Fast Track designation for BMS-986446 underscores the urgent unmet medical need in Alzheimer's and the FDA's efforts to expedite promising therapies. The company's focus on novel targets and therapeutic modalities like CYTOPE positions it at the forefront of innovative approaches to challenging diseases.

Comparison to Industry Standards

• Roche's stated peak sales potential for prasinezumab greater than $3.5 billion (unadjusted) indicates a significant market opportunity, comparable to other blockbuster drugs in neurodegenerative diseases if successful.
• The acquisition of Prothena's ATTR amyloidosis business and pipeline by Novo Nordisk for up to $1.2 billion reflects the high valuation and strategic importance of assets targeting rare diseases with significant unmet needs, aligning with industry trends of large pharma acquiring specialized biotech pipelines.
• Fast Track designation from the U.S. FDA for BMS-986446 is a common regulatory mechanism for drugs addressing serious conditions with unmet needs, similar to designations granted to other promising Alzheimer's therapies.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for capital return through a share redemption program in 2026, subject to EGM approval and board discretion. Continued investment in R&D and clinical pipeline advancement could lead to long-term value creation. Short-term, significant net losses and reduced revenue may impact sentiment.
• Employees: Workforce reduction announced in June 2025 (mentioned in restructuring charges) indicates past impact. Continued R&D efforts provide ongoing employment for scientific and clinical staff.
• Partners (Roche, Novo Nordisk, Bristol Myers Squibb): Continued collaboration and advancement of partnered programs strengthen relationships and demonstrate progress towards shared goals.
• Patients: Advancement of late-stage clinical trials for Parkinson's, Alzheimer's, and ATTR amyloidosis offers hope for new therapeutic options. Fast Track designation for BMS-986446 could expedite its availability.

Next Steps

• Novo Nordisk to present Phase 2 results for coramitug at American Heart Association Scientific Sessions on November 10, 2025.
• Prothena to convene an Extraordinary General Meeting on November 19, 2025, to vote on a share capital reduction proposal.
• Prothena scientists to present a poster on TDP-43 CYTOPE at Neuroscience 2025 on November 19, 2025.
• Roche to initiate Phase 3 PARAISO clinical trial for prasinezumab by the end of 2025.
• Bristol Myers Squibb to complete Phase 1 subcutaneous administration trial for BMS-986446 in 2H 2025.
• Prothena management to participate in Piper Sandler 37th Annual Healthcare Conference on December 3, 2025.
• Prothena management to participate in 8th Annual Evercore Healthcare Conference on December 4, 2025.
• Expect to earn a clinical milestone when prespecified enrollment criteria are met in the ongoing Phase 3 clinical trial for coramitug.
• Completion expected for PRX019 Phase 1 first-in-human clinical trial in 2026.
• Potential share redemption program in 2026, subject to board discretion.
• Primary completion expected for BMS-986446 Phase 2 TargetTau-1 clinical trial in 1H 2027.

Key Dates

Recommendation

While Prothena demonstrates strong progress in its late-stage clinical pipeline with multiple programs advancing to Phase 3 and receiving Fast Track designation, the company continues to report significant net losses and substantial cash burn. The proposed share redemption program offers a potential return of capital to shareholders, which is a positive, but the company remains in a development phase with no immediate path to profitability. The long-term potential is high given the unmet medical needs in its target diseases and the value of its partnerships, but the financial performance warrants a 'hold' until further clarity on clinical outcomes and a clearer path to commercialization emerges. Investors should monitor upcoming clinical data presentations and the outcome of the EGM.

Keywords

Prothena, PRTA, biotechnology, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, ATTR amyloidosis, prasinezumab, coramitug, BMS-986446, PRX019, clinical trials, Phase 3, Fast Track designation, financial results, Q3 2025, share redemption program, protein dysregulation, biopharma